Valneva SE (VALN) Revenue (2021 - 2026)
Valneva SE (VALN) posted Revenue of $36.2 million for Q1 2026, down 19.27% sequentially from $44.8 million in Q4 2025, and down 30.13% YoY from $51.8 million in Q1 2025.
Valneva SE (VALN) Revenue (2021 - 2026) Analysis & Trends
Valneva SE has reported Revenue for 6 years, with the latest figure at $36.2 million in Q1 2026.
- Quarterly Revenue fell 30.13% year-over-year to $36.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $161.2 million (down 16.39% YoY) and the FY2025 annual result came in at $183.8 million, up 3.99% from the prior year.
- Revenue fell to $36.2 million in Q1 2026 per VALN's latest filing, from $44.8 million in the prior quarter.
- Over five years, Revenue peaked at $158.0 million in Q3 2022 and troughed at $24.5 million in Q1 2022.
- A 5-year average of $54.6 million and a median of $44.8 million in 2025 frame the typical range for Revenue.
- The sharpest annual moves came in 2022 and 2023: Revenue soared 499.5% in 2022, then tumbled 73.77% in 2023.
- Over 5 years, Revenue stood at $113.7 million in 2022, then slumped by 60.34% to $45.1 million in 2023, then climbed by 20.42% to $54.3 million in 2024, then decreased by 17.44% to $44.8 million in 2025, then dropped by 19.27% to $36.2 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $36.2 million, $44.8 million, and $25.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | 40.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.61 Mn |
| Mar 31, 2026 | 36.18 Mn |
| Dec 31, 2025 | 44.82 Mn |
| Sep 30, 2025 | 25.53 Mn |
| Jun 30, 2025 | 54.71 Mn |
| Mar 31, 2025 | 51.79 Mn |
| Dec 31, 2024 | 54.28 Mn |
| Sep 30, 2024 | 45.78 Mn |
| Jun 30, 2024 | 40.99 Mn |
| Mar 31, 2024 | 35.58 Mn |
| Dec 31, 2023 | 45.08 Mn |
| Sep 30, 2023 | 41.44 Mn |
| Jun 30, 2023 | 43.81 Mn |
| Mar 31, 2023 | 35.97 Mn |
| Dec 31, 2022 | 113.66 Mn |
| Sep 30, 2022 | 157.97 Mn |
| Jun 30, 2022 | 76.16 Mn |
| Mar 31, 2022 | 24.52 Mn |
| Dec 31, 2021 | 318.30 Mn |
| Sep 30, 2021 | 26.35 Mn |